{"id":2403,"date":"2020-12-09T22:55:52","date_gmt":"2020-12-09T22:55:52","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=2403"},"modified":"2023-08-29T17:47:57","modified_gmt":"2023-08-29T17:47:57","slug":"immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=2403","title":{"rendered":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"<p>\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=IMM&amp;lang=cn\">Immutep (ASX: IMM)<\/a>\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002<\/p>\n<p>\u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0c\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684AIPAC(\u4e3b\u52a8\u514d\u75ab\u7597\u6cd5\u7d2b\u6749\u9187Active Immunotherapy Paclitaxel)IIb\u671f\u7814\u7a76\u53d6\u5f97\u4e86\u4ee4\u4eba\u9f13\u821e\u7684\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u65e8\u5728\u8bc4\u4f30\u8be5\u836f\u7269\u4e0e\u7d2b\u6749\u9187\u8054\u5408\u4f7f\u7528\u7684\u6548\u679c\u3002\u7d2b\u6749\u9187\u662f\u4e00\u79cd\u7528\u4e8e\u6cbb\u7597\u591a\u79cd\u764c\u75c7\u7684\u7d2b\u6749\u9187\u6807\u51c6\u5316\u7597\u836f\u7269\u3002<\/p>\n<p>EOC Pharma\u662fefti\u5728\u4e2d\u56fd\u5e02\u573a\u7684\u72ec\u5bb6\u8bb8\u53ef\u65b9\uff0c\u4f5c\u4e3a\u5176\u4e0eImmutep\u7684\u8bb8\u53ef\u534f\u8bae\u7684\u4e00\u90e8\u5206\uff0cEOC Pharma\u5fc5\u987b\u4e3aefti\u5728\u4e2d\u56fd\u7684\u7814\u53d1\u63d0\u4f9b\u8d44\u91d1\u3002<\/p>\n<h2>\u4e8c\u671f\u8bd5\u9a8c<\/h2>\n<p>II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u572820\u4e2a\u4e34\u5e8a\u4f4d\u70b9\u62db\u52df\u591a\u8fbe152\u540d\u60a3\u8005\uff0c\u4ee5\u7814\u7a76\u5728her2\u9634\u6027\/ hr\u9633\u6027\u7684\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u8fdb\u884c\u5185\u5206\u6ccc\u6cbb\u7597\u540e\u8fdb\u5c55\u60c5\u51b5\u4e0b\uff0ceftilagimod\u8054\u5408\u7d2b\u6749\u9187\u5316\u7597\u7684\u6548\u679c\u3002<\/p>\n<p>\u7814\u7a76\u7ec8\u70b9\u5305\u62ec\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\u3001\u603b\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002<\/p>\n<p>\u4e73\u817a\u764c\u662f\u4e2d\u56fd\u5973\u6027\u6700\u5e38\u89c1\u7684\u764c\u75c7\uff0c\u6bcf\u5e74\u6709\u8d85\u8fc7160\u4e07\u4eba\u88ab\u786e\u8bca\uff0c120\u4e07\u4eba\u6b7b\u4e8e\u6b64\u75c5\u3002<\/p>\n<h2>\u4ee4\u4eba\u9f13\u821e\u7684\u6570\u636e<\/h2>\n<p>Immutep\u7684\u9996\u5e2d\u6267\u884c\u5b98Marc Voigt\u8bf4\uff0cEOC\u7684\u8bd5\u9a8c\u5c06\u5efa\u7acb\u5728AIPAC\u7814\u7a76\u4ee4\u4eba\u9f13\u821e\u7684\u6570\u636e\u57fa\u7840\u4e0a\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201cAIPAC\u5bf9\u6211\u4eec\u6765\u8bf4\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u91cc\u7a0b\u7891\uff0c\u5b83\u4f7f\u6211\u4eec\u76f8\u4fe1efti\u5bf9\u8bb8\u591a\u764c\u75c7\u60a3\u8005\u6709\u76ca\uff0c\u5305\u62ec\u90a3\u4e9b\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u3002\u201d<\/p>\n<p>\u201cEOC\u7684\u65b0\u8bd5\u9a8c\u5c06\u4f7f\u8fd9\u79cd\u521b\u65b0\u7597\u6cd5\u66f4\u63a5\u8fd1\u5e02\u573a\u3002\u201d<\/p>\n<p>Voigt\u8bc1\u5b9e\uff0cEOC\u4ece\u4e2d\u56fd\u56fd\u5bb6\u533b\u7597\u4ea7\u54c1\u7ba1\u7406\u5c40(National Medical Products Administration)\u5f97\u5230\u4e86\u79ef\u6781\u7684\u79d1\u5b66\u5efa\u8bae\uff0c\u4f7f\u9996\u4f8b\u60a3\u8005\u5f97\u4ee5\u57282021\u5e74\u7b2c\u4e00\u5b63\u5ea6\u53c2\u52a0\u8bd5\u9a8c\u5e76\u670d\u7528\u836f\u7269\u3002<\/p>\n<h2>AIPAC\u7684\u7ed3\u679c<\/h2>\n<p>AIPAC\u4eca\u5929\u516c\u5e03\u7684\u7597\u6548\u7ed3\u679c\u8868\u660e\uff0c\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u6cbb\u7597\u4e0d\u654f\u611f\u7684\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u6709\u201c\u7edf\u8ba1\u4e0a\u663e\u8457\u7684\u603b\u4f53\u751f\u5b58\u83b7\u76ca\u201d\u3002<\/p>\n<p>\u7ed3\u679c\u663e\u793a\uff0c\u603b\u751f\u5b58\u7387\u5728\u603b\u4eba\u53e3\u4e2d\u6709\u826f\u597d\u7684\u6539\u5584\u8d8b\u52bf;\u4e0e\u5316\u7597\u52a0\u5b89\u6170\u5242\u76f8\u6bd4\uff0cefti\u52a0\u5316\u7597\u7684\u4e2d\u4f4d\u751f\u5b58\u83b7\u76ca\u4e3a2.7\u4e2a\u6708\u3002<\/p>\n<p>65\u5c81\u4ee5\u4e0b\u7684\u60a3\u8005(\u5360efti\u7ec4\u768466.7%)\u663e\u793aefti\u52a0\u5316\u7597\u7684\u751f\u5b58\u83b7\u76ca\u8d85\u8fc77.1\u4e2a\u6708\uff0c\u800c\u90a3\u4e9b\u5f00\u59cb\u5355\u6838\u7ec6\u80de\u8ba1\u6570\u8f83\u4f4e\u7684\u60a3\u8005(\u5360\u7ec4\u768421.9%)\u7684\u751f\u5b58\u83b7\u76ca\u8d85\u8fc79.4\u4e2a\u6708\u3002<\/p>\n<p>\u8be5\u7814\u7a76\u8fd8\u663e\u793a\uff0c\u5728\u63a5\u53d7efti\u8054\u5408\u5316\u7597\u7684\u60a3\u8005\u4e2d\uff0cCD8(\u7ec6\u80de\u6bd2\u6027)T\u7ec6\u80de\u663e\u8457\u589e\u52a0\uff0c\u8fd9\u4e0e\u5ef6\u957f\u603b\u4f53\u751f\u5b58\u65f6\u95f4\u6709\u5173\uff0c\u5e76\u8868\u660eefti\u7684\u4f5c\u7528\u6a21\u5f0f\u7684\u836f\u6548\u5b66\u6d3b\u6027\u548c\u6982\u5ff5\u9a8c\u8bc1\u3002<\/p>\n<h2>\u5173\u952e\u7684\u7aef\u70b9<\/h2>\n<p>Voigt\u5148\u751f\u8bf4\uff0c\u63d0\u9ad8\u6574\u4f53\u5b58\u6d3b\u7387\u662f\u8bc4\u4f30\u65b0\u6297\u764c\u836f\u7269\u7597\u6548\u7684\u4e00\u4e2a\u5173\u952e\u7ec8\u70b9\u3002<\/p>\n<p>\u201c\u503c\u5f97\u6ce8\u610f\u7684\u662f,\u6211\u4eec\u770b\u5230\u66f4\u591a\u7684\u7269\u8d28\u6574\u4f53\u751f\u5b58\u5229\u76ca\u6bd4\u65e0\u8fdb\u5c55\u751f\u5b58\u5229\u76ca\u7136\u800c\u5728\u8fd9\u9879\u7814\u7a76\u4e2d\u6211\u4eec\u77e5\u9053\u8fd9\u4e0d\u662f\u4e0d\u5bfb\u5e38\u7684\u4e00\u4e9b\u514d\u75ab\u7597\u6cd5\u53ef\u4ee5\u82b1\u65f6\u95f4\u8eab\u4f53\u7684\u514d\u75ab\u7cfb\u7edf\u662f\u63d0\u9ad8\u5e76\u63d0\u4f9b\u6cbb\u7597\u7684\u597d\u5904,\u201d\u4ed6\u8bf4\u3002<\/p>\n<p>\u201c\u6211\u4eec\u5bf9AIPAC\u7684\u8fd9\u4e9b\u9996\u6b21\u7814\u7a76\u7ed3\u679c\u611f\u5230\u975e\u5e38\u9f13\u821e\uff0c\u8fd9\u4e9b\u7ed3\u679c\u53d6\u51b3\u4e8e\u6b63\u5728\u8fdb\u884c\u7684\u6570\u636e\u6536\u96c6\uff0c\u6211\u4eec\u5e0c\u671b\u8fd9\u5c06\u662f\u4e00\u79cd\u91cd\u8981\u7684\u65b0\u578b\u836f\u7269\uff0c\u9700\u8981\u4ece\u6ce8\u518c\u7684\u89d2\u5ea6\u548c\u76d1\u7ba1\u7684\u76f8\u4e92\u4f5c\u7528\u6765\u770b\u3002\u201d<\/p>\n<p>\u8fd9\u4e9b\u6570\u636e\u652f\u6301\u4e86Immutep\u957f\u671f\u4ee5\u6765\u7684\u4fe1\u5ff5\uff0c\u5373efti\u53ef\u4ee5\u901a\u8fc7\u5bf9\u4eba\u4f53\u514d\u75ab\u7cfb\u7edf\u7684\u201c\u65bd\u538b\u201d\uff0c\u4e3a\u4e00\u7cfb\u5217\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u6709\u610f\u4e49\u7684\u597d\u5904\u3002<\/p>\n<p>\u201c\u901a\u8fc7\u8fd9\u4e00\u673a\u5236\uff0cefti\u6b63\u5728\u5e2e\u52a9AIPAC\u7814\u7a76\u4e2dher2\u9634\u6027\/ hr\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u5927\u90e8\u5206\u60a3\u8005\uff0c\u8fd9\u662f\u4e00\u79cd\u5178\u578b\u7684\u975e\u514d\u75ab\u6e90\u6027\u764c\u75c7\uff0c\u5bf9\u73b0\u4ee3\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7597\u6cd5\u7684\u53cd\u5e94\u660e\u663e\u8f83\u5f31\uff0c\u201dVoigt\u5148\u751f\u8bf4\u3002<\/p>\n<p>\u201c\u56e0\u6b64\uff0c\u5728\u8bb8\u591a\u60c5\u51b5\u4e0b\uff0c\u5316\u7597\u4ecd\u662f\u6807\u51c6\u7684\u6cbb\u7597\uff0c\u4ecd\u7136\u6709\u5927\u91cf\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002 \u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0c\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684AIPAC(\u4e3b\u52a8\u514d\u75ab\u7597\u6cd5\u7d2b\u6749\u9187Active Immunotherapy Paclitaxel)IIb\u671f\u7814\u7a76\u53d6\u5f97\u4e86\u4ee4\u4eba\u9f13\u821e\u7684\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u65e8\u5728\u8bc4\u4f30\u8be5\u836f\u7269\u4e0e\u7d2b\u6749\u9187\u8054\u5408\u4f7f\u7528\u7684\u6548\u679c\u3002\u7d2b\u6749\u9187\u662f\u4e00\u79cd\u7528\u4e8e\u6cbb\u7597\u591a\u79cd\u764c\u75c7\u7684\u7d2b\u6749\u9187\u6807\u51c6\u5316\u7597\u836f\u7269\u3002 EOC Pharma\u662fefti\u5728\u4e2d\u56fd\u5e02\u573a\u7684\u72ec\u5bb6\u8bb8\u53ef\u65b9\uff0c\u4f5c\u4e3a\u5176\u4e0eImmutep\u7684\u8bb8\u53ef\u534f\u8bae\u7684\u4e00\u90e8\u5206\uff0cEOC Pharma\u5fc5\u987b\u4e3aefti\u5728\u4e2d\u56fd\u7684\u7814\u53d1\u63d0\u4f9b\u8d44\u91d1\u3002 \u4e8c\u671f\u8bd5\u9a8c II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u572820\u4e2a\u4e34\u5e8a\u4f4d\u70b9\u62db\u52df\u591a\u8fbe152\u540d\u60a3\u8005\uff0c\u4ee5\u7814\u7a76\u5728her2\u9634\u6027\/ hr\u9633\u6027\u7684\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u8fdb\u884c\u5185\u5206\u6ccc\u6cbb\u7597\u540e\u8fdb\u5c55\u60c5\u51b5\u4e0b\uff0ceftilagimod\u8054\u5408\u7d2b\u6749\u9187\u5316\u7597\u7684\u6548\u679c\u3002 \u7814\u7a76\u7ec8\u70b9\u5305\u62ec\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\u3001\u603b\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002 \u4e73\u817a\u764c\u662f\u4e2d\u56fd\u5973\u6027\u6700\u5e38\u89c1\u7684\u764c\u75c7\uff0c\u6bcf\u5e74\u6709\u8d85\u8fc7160\u4e07\u4eba\u88ab\u786e\u8bca\uff0c120\u4e07\u4eba\u6b7b\u4e8e\u6b64\u75c5\u3002 \u4ee4\u4eba\u9f13\u821e\u7684\u6570\u636e Immutep\u7684\u9996\u5e2d\u6267\u884c\u5b98Marc Voigt\u8bf4\uff0cEOC\u7684\u8bd5\u9a8c\u5c06\u5efa\u7acb\u5728AIPAC\u7814\u7a76\u4ee4\u4eba\u9f13\u821e\u7684\u6570\u636e\u57fa\u7840\u4e0a\u3002 \u4ed6\u8bf4:\u201cAIPAC\u5bf9\u6211\u4eec\u6765\u8bf4\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u91cc\u7a0b\u7891\uff0c\u5b83\u4f7f\u6211\u4eec\u76f8\u4fe1efti\u5bf9\u8bb8\u591a\u764c\u75c7\u60a3\u8005\u6709\u76ca\uff0c\u5305\u62ec\u90a3\u4e9b\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u3002\u201d \u201cEOC\u7684\u65b0\u8bd5\u9a8c\u5c06\u4f7f\u8fd9\u79cd\u521b\u65b0\u7597\u6cd5\u66f4\u63a5\u8fd1\u5e02\u573a\u3002\u201d Voigt\u8bc1\u5b9e\uff0cEOC\u4ece\u4e2d\u56fd\u56fd\u5bb6\u533b\u7597\u4ea7\u54c1\u7ba1\u7406\u5c40(National Medical Products Administration)\u5f97\u5230\u4e86\u79ef\u6781\u7684\u79d1\u5b66\u5efa\u8bae\uff0c\u4f7f\u9996\u4f8b\u60a3\u8005\u5f97\u4ee5\u57282021\u5e74\u7b2c\u4e00\u5b63\u5ea6\u53c2\u52a0\u8bd5\u9a8c\u5e76\u670d\u7528\u836f\u7269\u3002 AIPAC\u7684\u7ed3\u679c AIPAC\u4eca\u5929\u516c\u5e03\u7684\u7597\u6548\u7ed3\u679c\u8868\u660e\uff0c\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u6cbb\u7597\u4e0d\u654f\u611f\u7684\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u6709\u201c\u7edf\u8ba1\u4e0a\u663e\u8457\u7684\u603b\u4f53\u751f\u5b58\u83b7\u76ca\u201d\u3002 \u7ed3\u679c\u663e\u793a\uff0c\u603b\u751f\u5b58\u7387\u5728\u603b\u4eba\u53e3\u4e2d\u6709\u826f\u597d\u7684\u6539\u5584\u8d8b\u52bf;\u4e0e\u5316\u7597\u52a0\u5b89\u6170\u5242\u76f8\u6bd4\uff0cefti\u52a0\u5316\u7597\u7684\u4e2d\u4f4d\u751f\u5b58\u83b7\u76ca\u4e3a2.7\u4e2a\u6708\u3002 65\u5c81\u4ee5\u4e0b\u7684\u60a3\u8005(\u5360efti\u7ec4\u768466.7%)\u663e\u793aefti\u52a0\u5316\u7597\u7684\u751f\u5b58\u83b7\u76ca\u8d85\u8fc77.1\u4e2a\u6708\uff0c\u800c\u90a3\u4e9b\u5f00\u59cb\u5355\u6838\u7ec6\u80de\u8ba1\u6570\u8f83\u4f4e\u7684\u60a3\u8005(\u5360\u7ec4\u768421.9%)\u7684\u751f\u5b58\u83b7\u76ca\u8d85\u8fc79.4\u4e2a\u6708\u3002 \u8be5\u7814\u7a76\u8fd8\u663e\u793a\uff0c\u5728\u63a5\u53d7efti\u8054\u5408\u5316\u7597\u7684\u60a3\u8005\u4e2d\uff0cCD8(\u7ec6\u80de\u6bd2\u6027)T\u7ec6\u80de\u663e\u8457\u589e\u52a0\uff0c\u8fd9\u4e0e\u5ef6\u957f\u603b\u4f53\u751f\u5b58\u65f6\u95f4\u6709\u5173\uff0c\u5e76\u8868\u660eefti\u7684\u4f5c\u7528\u6a21\u5f0f\u7684\u836f\u6548\u5b66\u6d3b\u6027\u548c\u6982\u5ff5\u9a8c\u8bc1\u3002 \u5173\u952e\u7684\u7aef\u70b9 Voigt\u5148\u751f\u8bf4\uff0c\u63d0\u9ad8\u6574\u4f53\u5b58\u6d3b\u7387\u662f\u8bc4\u4f30\u65b0\u6297\u764c\u836f\u7269\u7597\u6548\u7684\u4e00\u4e2a\u5173\u952e\u7ec8\u70b9\u3002 \u201c\u503c\u5f97\u6ce8\u610f\u7684\u662f,\u6211\u4eec\u770b\u5230\u66f4\u591a\u7684\u7269\u8d28\u6574\u4f53\u751f\u5b58\u5229\u76ca\u6bd4\u65e0\u8fdb\u5c55\u751f\u5b58\u5229\u76ca\u7136\u800c\u5728\u8fd9\u9879\u7814\u7a76\u4e2d\u6211\u4eec\u77e5\u9053\u8fd9\u4e0d\u662f\u4e0d\u5bfb\u5e38\u7684\u4e00\u4e9b\u514d\u75ab\u7597\u6cd5\u53ef\u4ee5\u82b1\u65f6\u95f4\u8eab\u4f53\u7684\u514d\u75ab\u7cfb\u7edf\u662f\u63d0\u9ad8\u5e76\u63d0\u4f9b\u6cbb\u7597\u7684\u597d\u5904,\u201d\u4ed6\u8bf4\u3002 \u201c\u6211\u4eec\u5bf9AIPAC\u7684\u8fd9\u4e9b\u9996\u6b21\u7814\u7a76\u7ed3\u679c\u611f\u5230\u975e\u5e38\u9f13\u821e\uff0c\u8fd9\u4e9b\u7ed3\u679c\u53d6\u51b3\u4e8e\u6b63\u5728\u8fdb\u884c\u7684\u6570\u636e\u6536\u96c6\uff0c\u6211\u4eec\u5e0c\u671b\u8fd9\u5c06\u662f\u4e00\u79cd\u91cd\u8981\u7684\u65b0\u578b\u836f\u7269\uff0c\u9700\u8981\u4ece\u6ce8\u518c\u7684\u89d2\u5ea6\u548c\u76d1\u7ba1\u7684\u76f8\u4e92\u4f5c\u7528\u6765\u770b\u3002\u201d \u8fd9\u4e9b\u6570\u636e\u652f\u6301\u4e86Immutep\u957f\u671f\u4ee5\u6765\u7684\u4fe1\u5ff5\uff0c\u5373efti\u53ef\u4ee5\u901a\u8fc7\u5bf9\u4eba\u4f53\u514d\u75ab\u7cfb\u7edf\u7684\u201c\u65bd\u538b\u201d\uff0c\u4e3a\u4e00\u7cfb\u5217\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u6709\u610f\u4e49\u7684\u597d\u5904\u3002 \u201c\u901a\u8fc7\u8fd9\u4e00\u673a\u5236\uff0cefti\u6b63\u5728\u5e2e\u52a9AIPAC\u7814\u7a76\u4e2dher2\u9634\u6027\/ hr\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u5927\u90e8\u5206\u60a3\u8005\uff0c\u8fd9\u662f\u4e00\u79cd\u5178\u578b\u7684\u975e\u514d\u75ab\u6e90\u6027\u764c\u75c7\uff0c\u5bf9\u73b0\u4ee3\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7597\u6cd5\u7684\u53cd\u5e94\u660e\u663e\u8f83\u5f31\uff0c\u201dVoigt\u5148\u751f\u8bf4\u3002 \u201c\u56e0\u6b64\uff0c\u5728\u8bb8\u591a\u60c5\u51b5\u4e0b\uff0c\u5316\u7597\u4ecd\u662f\u6807\u51c6\u7684\u6cbb\u7597\uff0c\u4ecd\u7136\u6709\u5927\u91cf\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u201d<\/p>\n","protected":false},"author":4,"featured_media":10301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[303],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T22:55:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:47:57+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Immutep-EOC-Pharma-ASX-IMM-metastatic-breast-cancer-efti.jpg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta name=\"twitter:description\" content=\"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Immutep-EOC-Pharma-ASX-IMM-metastatic-breast-cancer-efti.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/\",\"name\":\"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-12-09T22:55:52+00:00\",\"dateModified\":\"2023-08-29T17:47:57+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c","description":"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c","og_description":"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/","og_site_name":"smallcapsCN","article_published_time":"2020-12-09T22:55:52+00:00","article_modified_time":"2023-08-29T17:47:57+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Immutep-EOC-Pharma-ASX-IMM-metastatic-breast-cancer-efti.jpg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_title":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c","twitter_description":"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Immutep-EOC-Pharma-ASX-IMM-metastatic-breast-cancer-efti.jpg","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/","url":"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/","name":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-12-09T22:55:52+00:00","dateModified":"2023-08-29T17:47:57+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u5168\u7403\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u5ba3\u5e03\uff0c\u5176\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34EOC Pharma\u5c06\u5f00\u59cb\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5148\u5bfc\u836f\u7269eftilagimod\u6cbb\u7597\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/immutep-chinese-partner-phase-ii-clinical-trial-metastatic-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Immutep\u7684\u4e2d\u56fd\u5408\u4f5c\u4f19\u4f34\u542f\u52a8\u4e86\u9488\u5bf9\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2403"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2403"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2403\/revisions"}],"predecessor-version":[{"id":10300,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2403\/revisions\/10300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/10301"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}